229 related articles for article (PubMed ID: 33128780)
41. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
Aref-Eshghi E; Lin F; Li MM; Zhong Y
Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
[TBL] [Abstract][Full Text] [Related]
42. Identification of NTRK fusions in pediatric mesenchymal tumors.
Pavlick D; Schrock AB; Malicki D; Stephens PJ; Kuo DJ; Ahn H; Turpin B; Allen JM; Rosenzweig M; Badizadegan K; Ross JS; Miller VA; Wong V; Ali SM
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28097808
[TBL] [Abstract][Full Text] [Related]
43. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
44. NTRK-rearranged spindle cell neoplasms are ubiquitous tumours of myofibroblastic lineage with a distinct methylation class.
Tauziède-Espariat A; Duchesne M; Baud J; Le Quang M; Bochaton D; Azmani R; Croce S; Hostein I; Kesrouani C; Guillemot D; Pierron G; Bourdeaut F; Cardoen L; Hasty L; Lechapt E; Métais A; Chrétien F; Puget S; Varlet P; Le Loarer F
Histopathology; 2023 Mar; 82(4):596-607. PubMed ID: 36413100
[TBL] [Abstract][Full Text] [Related]
45. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract][Full Text] [Related]
46. ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.
Tan SY; Al-Ibraheemi A; Ahrens WA; Oesterheld JE; Fanburg-Smith JC; Liu YJ; Spunt SL; Rudzinski ER; Coffin C; Davis JL
Histopathology; 2022 Mar; 80(4):698-707. PubMed ID: 34843129
[TBL] [Abstract][Full Text] [Related]
47. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
Garrido P; Hladun R; de Álava E; Álvarez R; Bautista F; López-Ríos F; Colomer R; Rojo F
Clin Transl Oncol; 2021 Aug; 23(8):1529-1541. PubMed ID: 33620682
[TBL] [Abstract][Full Text] [Related]
48. Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors.
Dufresne A; Pissaloux D; Ngo C; Penel N; Le Cesne A; Macagno N; Vanacker H; Hénon C; Jean-Denis M; Rughoo K; Tirode F; Blay JY; Brahmi M
ESMO Open; 2023 Apr; 8(2):101202. PubMed ID: 37054503
[TBL] [Abstract][Full Text] [Related]
49. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
[TBL] [Abstract][Full Text] [Related]
50. NTRK fusions in solid tumours: what every pathologist needs to know.
Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
[TBL] [Abstract][Full Text] [Related]
51. Detection of
Solomon JP; Hechtman JF
Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931
[TBL] [Abstract][Full Text] [Related]
52. Novel fusion sarcomas including targetable NTRK and ALK.
Chen T; Wang Y; Goetz L; Corey Z; Dougher MC; Smith JD; Fox EJ; Freiberg AS; Flemming D; Fanburg-Smith JC
Ann Diagn Pathol; 2021 Oct; 54():151800. PubMed ID: 34464935
[TBL] [Abstract][Full Text] [Related]
53. Expanding the Spectrum of Adult NTRK3-Rearranged Spindle Cell Neoplasms: A Recurrent NTRK3-SQSTM1 Fusion Spindle Cell Tumor With Deceptively Bland Morphology.
Punjabi LS; Sittampalam K
Am J Clin Pathol; 2022 Apr; 157(4):485-493. PubMed ID: 34661642
[TBL] [Abstract][Full Text] [Related]
54. NTRK fusions and Trk proteins: what are they and how to test for them.
Weiss LM; Funari VA
Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
[TBL] [Abstract][Full Text] [Related]
55. Cost-Efficient Detection of
Romanko AA; Mulkidjan RS; Tiurin VI; Saitova ES; Preobrazhenskaya EV; Krivosheyeva EA; Mitiushkina NV; Shestakova AD; Belogubova EV; Ivantsov AO; Iyevleva AG; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762506
[TBL] [Abstract][Full Text] [Related]
56. Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors.
Davis JL; Lockwood CM; Stohr B; Boecking C; Al-Ibraheemi A; DuBois SG; Vargas SO; Black JO; Cox MC; Luquette M; Turpin B; Szabo S; Laetsch TW; Albert CM; Parham DM; Hawkins DS; Rudzinski ER
Am J Surg Pathol; 2019 Apr; 43(4):435-445. PubMed ID: 30585824
[TBL] [Abstract][Full Text] [Related]
57. p53 immunohistochemical analysis of fusion-positive uterine sarcomas.
Mohammad N; Stewart CJR; Chiang S; Turashvili G; Dickson BC; Ng TL; Köbel M; McCluggage WG; Croce S; Lee CH
Histopathology; 2021 May; 78(6):805-813. PubMed ID: 33118176
[TBL] [Abstract][Full Text] [Related]
58. NTRK point mutations and their functional consequences.
Rogers C; Morrissette JJD; Sussman RT
Cancer Genet; 2022 Apr; 262-263():5-15. PubMed ID: 34972036
[TBL] [Abstract][Full Text] [Related]
59. Primary NTRK-rearranged spindle cell neoplasm of bone harboring an HMBOX1::NTRK3 gene fusion.
Wang Z; Wang J
Genes Chromosomes Cancer; 2023 Aug; 62(8):477-482. PubMed ID: 36740981
[TBL] [Abstract][Full Text] [Related]
60. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
